Navigation Links
Cholesterol Drug Fails to Slow Progression of Coronary Disease,,Cleveland Clinic Study Reports

P Inhibition and HDL Elevation" (ILLUSTRATE) trial. All patients had a clinical indication for cardiac catheterization, had a baseline intravascular ultrasound (IVUS) and received 10-80 gm of atorvastatin adjusted during a two- to 10-week period until LDL levels reached national guidelines.

Patients were then randomized to receive either 60 mg of torcetrapib or a matching placebo for two years. At the end of the treatment period, a second IVUS was performed, examining the same coronary arteries. Researchers measured the change in plaque volume in the artery, comparing the baseline to the follow-up ultrasound. They also measured patients' blood cholesterol levels and biomarkers of inflammation at several points during the trial.

Patients in the torcetrapib/atorvastatin group experienced a 61 percent relative increase in HDL cholesterol levels and a 20 percent relative decrease in LDL levels, as compared with patients in the atorvastatin-only group. Despite those results, there was no statistical difference between the two groups in plaque volume changes. Plaque volume increased by 0.19 percent in the atorvastatin-only patients and 0.12 percent in the combination group, p = 0.72. Torectrapib was also associated with a substantial increase in blood pressure, averaging 4.6 mm.

IVUS is a technique in which a tiny ultrasound probe is inserted into the coronary arteries, providing a precise and reproducible method for determining the change in plaque, or atheroma, burden during treatment.

Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
4. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
5. CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries
6. CSL Therapy That Mimics Good Cholesterol May Reduce Plaque Volume in Coronary Arteries
7. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
8. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
9. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
Post Your Comments:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Quetiapine Market, 2010-2019" ... by AstraZeneca plc, quetiapine (under the trade name ... treatment of schizophrenia. Approved by CFDA to treat ... Catalogue of Drugs for the Basic National Medical ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... 2007 /PRNewswire-FirstCall/ --,SuperGen Inc. announced today that it ... Cancer Research,Annual Meeting on April 14-18 in Los ... of SuperGen's current oncology,programs including its lead tyrosine ... Rad51, a key protein target involved,in cancer cell ...
... -- CytImmune, a,clinical stage nanomedicine company focused ... has,been selected to present a poster abstract at ... in Chicago Illinois,June 1-5. The poster session will ... June 3. Dr. Lawrence Tamarkin, CEO of CytImmune ...
Cached Medicine Technology:SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 2SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 4CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President of ... increase acceptance of the chiropractic field in the military. All too often VA hospitals ... Chiropractic was made available to the VA program over a decade ago, the reality ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of the stage ... short segment to the subject of diabetes. Diabetes is a debilitating health condition that ... recent advancements in medical science may prove to be a significant breakthrough that sufferers ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number of ... transitioned management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce ... the position they are applying for, they are unable to pass the initial drug ... altering drug testing policies in order to be able to hire long-term, skilled talent. ...
Breaking Medicine News(10 mins):Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... Help Plan Members Better Manage Healthcare Needs and Spending , ... Life Insurance Company of America (Guardian), one of the largest ... voluntary benefits for small and mid-sized companies, today introduced enhanced ... their employees will now have access to a broad range ...
... Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical ... novel drugs in the therapeutic areas of infection, oncology ... the first quarter ended March 31, 2009. The ... months ended March 31, 2009 was $2.3 million or ...
... ,Eliminates Complications Including Right Heart Failure , ... ... to INTERMACS data recently published in SynCardia’s 2008 Annual ... a bridge-to-transplant rate of 72% at 6 months. This is ...
... Call to Action demonstrates commitment to combating a leading ... and WaterAid America released two new reports today that ... are not responding to clear evidence on child mortality ... Diarrheal disease, a leading killer of children under age ...
... www.hairfairies.com ) opens new salon to help San Diego,s frantic families ... 12 Hair Fairies, the head lice helpers, ( www.hairfairies.com ) ... lice removal salon in San Diego on May 12, 2009. ... a nationwide, full service salon dedicated to removing head lice. ...
... 12 Miami and NY-based Jeffrey Epstein, M.D., FACS, ... has recently established The Foundation for Hair Restoration and ... surgical hair restoration and plastic surgeons. Recognized for ... will help to position The Foundation for Hair Restoration ...
Cached Medicine News:Health News:Guardian Enhances Medical Plans With New Wellness Benefits 2Health News:Guardian Enhances Medical Plans With New Wellness Benefits 3Health News:Guardian Enhances Medical Plans With New Wellness Benefits 4Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 2Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 3Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 4Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 5Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 6Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 7Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 8Health News:Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook 9Health News:INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher ,at 6 Months Than BiVADS and LVADs 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 3Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 4Health News:Lice Removal Salon Offers San Diego an Upscale Solution to an Undesirable Problem 2Health News:Foundation for Hair Restoration Brings Breakthrough Surgical Technology to the U.S. and Announces Nationwide Expansion of Its Network of Top Doctors 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: